Expression, purification and bioactivity of recombinant human bone morphogenetic protein-4,-9,-10,-11 and-14 produced in Escherichia coli for tissue engineering applications by Bessa, P. C. et al.
(P 167) Expression and Puriﬁcation of Recombinant Aprotinin
for Enhanced Stability of Fibrin Biomaterials
K.M. Lorentz1, P. Frey1, J.A. Hubbell1
1Ecole Polytechnique Federale de Lausanne.
Fibrin is an integral component of the clot during wound healing
and can be harvested autologously for creation of biologically
active, biocompatible, hydrogel matrices. However, ﬁbrin gels can
lose utility due to their rapid rate of degradation via the actions of
plasmin, especially in the context of the in vivo environment.
Covalent-binding of plasmin-inhibitors to the matrix would allow
for prolonged stability of ﬁbrin while bypassing any alterations in
its structure. Previous studies have successfully bound bioactive
factors to ﬁbrin matrices via a transglutaminase (TG) factor XIIIa
substrate sequence tag, derived from a2-plasmin inhibitor. Using
standand cloning techniques, a recombinant protein, aprotininTG,
was created by fusing the TG-substrate sequence onto the
C-terminus of the plasmin inhibitor, aprotinin. AprotininTG was
then expressed in Escherichia coli and was puriﬁed from crude cell
lysate using GST afﬁnity chromatography. Bioactivity of the re-
combinant protein was assessed via a plasmin-inhibition assay.
Thus, a mutant form of aprotinin has been created as a fusion
protein which allows for efﬁcient covalent cross-linking of the
plasmin inhibitor into ﬁbrin matrices. Use of aprotininTG within
ﬁbrin matrices may reduce their rate of degradation and therefore
further augment their utility as biomaterials.
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Bone morphogenetic proteins (BMPs) are cytokines from the TGF-
b superfamily, with important roles during embryonic develop-
ment and in inducing bone and cartilage in the adult body. In
this contribution, we report the expression of recombinant
human BMP-4, BMP-9, BMP-10, BMP-11 (or growth differenti-
ation factor-11, GDF-11) and BMP-14 (GDF-5), using Escherichia
coli pET-25b expression system. The BMPs were puriﬁed by
afﬁnity chromatography and its bioactivity accessed in C2C12
cell line, by screening the expression of osteogenic markers with
RT-PCR. The expression of Smad-1, Smad-3, Smad-5, Runx2/
cbfa1, Osterix, Bone sialoprotein, Osteopontin and ALP was
increased with some or all of these BMPs, while Smad-7 was
down-regulated, coinciding with the different changes in cell
morphology. No cytotoxicity was observed and around 200mg of
BMPs were puriﬁed per Liter of batch. Ongoing work includes
bioactivity assays in human adipose stem cells and with the effect
of heparin on the BMP activity. The approach described here is a
promising method for producing large scale amounts of recombi-
nant BMPs, in pure and bioactive form, for novel biomedical ap-
plications.
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This work reported of eleven cases of early spontaneous osteone-
crosis of the knee successfully treated with a novel extracorporeal
shockwave treatment.
Traumatic and vascular theories have been proposed as a caus-
ative factor of spontaneous osteonecrosis of the knee, but precise
etiology still remains speculative.
ESWT, thanks to its neo-angiogenetic effect, can be suggested
as an effective regenerative treatment for spontaneous osteone-
crosis of the knee.
Ten patients with medial femoral condyle spontaneous osteo-
necrosis of the knee were evaluated. Exclusion criteria was evi-
dence of structural collapse of subchondral bone. Two patients had
received femoro-popliteal by-pass, while others ﬁve presented
deﬁcit of the vascular axis of the homolateral lower limb docu-
mented by an eco-colordoppler. Clinical evaluation was taken at
diagnosis using KSS, McGill Pain Questionnaire.
Patients were treated with a cycle of three ESWT performed
with 2000 pulses of 0,28 mJ/mm2 with Wolf Piezoson 300 with
6,5MHz ultrasounds for three times in a month.
Clinical evaluation was performed at ﬁrst and at third month
after treatment and a RMI evaluation was performed at fourth
month after the treatment.
Clinical evaluation showed signiﬁcant improvement of symp-
toms (p<0.001) and articular functionality (p< 0.001). MRI of all
cases revealed the continuity of the cartilage with a reduction in
bone marrow edema and no collapse of lesion; in one case the total
recover up to a normal signal in the subcondral bone was docu-
mented.
Therefore, a single cycle of ESWT produced an improvement of
clinical and MRI aspects in eleven cases of spontaneous osteone-
crosis of the knee.
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